GSK Announced US FDA Approved Priorix To Prevent Measles, Rubella and Mumps


GSK Plc. Announced that, the Food and Drug Administration (FDA) of the United States has now approved Priorix for the active immunisation to prevent the individuals from measles, mumps and rubella (MMR), which are 12 months of age and older.

Priorix has currently been licenced in over 100 countries across the world including all the European countries, along with Canada, Australia and New Zealand with more than 100 million doses distributed till date.

Judy Stewart, senior vice president and head of the vaccines at GSK said, they are proud for making the vaccine more available in the United States for the first time, which will be adding a choice for the providers to help in protecting the patients against all the highly-contagious diseases and also further strengthening the offerings in their paediatric vaccine portfolio.

The Measles, mumps and rubella have been acute and highly-contagious viral diseases that are responsible for considerable morbidity and the mortality throughout the world. Recently, the outbreaks of measles have been occurred in the United States and across the globe along with over 400,000 cases have been confirmed in 2019 along with reversing the decades of progress towards the elimination of measles in most of the countries.

See also  US FDA Accepts New Drug Application of Astellas for Fezolinetant

According to the US CDC, the vaccine ordering in the previous two years through the Vaccine For Children program of US CDC and the report has also noted 400,000 lesser children that have entered kindergarten in 2020-2021 school year than it was expected nationally.